drugset / Trial / NCT01789723
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent or reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment.
Timeline
- Start
- 2013-03
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levoleucovorin | Unknown | 5 mg/m2 | Intravenous |
| Background | Pralatrexate | Other / unclassified | 30 mg/m2 | — |